LNK01002

LNK01002 is an orally bioavailable, innovative triple kinase inhibitor developed by Lynk Pharmaceuticals. It is designed to simultaneously inhibit three kinases—FLT3, JAK1, and JAK2—which are key drivers in certain hematological malignancies such as primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PV-MF), post-essential thrombocythemia myelofibrosis (ET-MF), polycythemia vera (PV), and acute myeloid leukemia (AML). The drug acts by inhibiting the activity of these kinases, thereby exerting antineoplastic effects. As a proteolysis-targeting chimera (PROTAC) molecule, it may also promote targeted degradation of these proteins via the ubiquitin–proteasome system. LNK01002 is currently in phase I clinical trials for patients with malignant myeloid hematologic neoplasms who are unresponsive or resistant to conventional therapies[1][2][3][4][5].